Effect of Sleep Disorder on the Development of Lung Tumors
NCT ID: NCT05745506
Last Updated: 2023-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
200 participants
OBSERVATIONAL
2023-02-28
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* will long-term sleep disorder promote the malignancy of lung tumor
* if so, how exactly will the microenvironment of lung tumor change Participants will receive PSQI scale and MRI functional brain imaging before surgery, blood and tumor tissue will be collected during the surgery.
Researchers will set non-sleep disorder group as control group to see if lung tumor microenvironment change when long-term sleep disorder exists in lung tumor patiens.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sleep State in Lung Cancer: A Retrospective Analysis
NCT06953492
Sleep Disorders and Tumor Immune Microenvironment
NCT06941948
Sleep Disturbance in Lung Cancer Patients.
NCT00187980
The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
NCT06975384
Identification and Characterisation of Sleep Disorders in a Population of Patients With Non-small Cell Lung Cancer
NCT06495346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRD
patients whose PSQI score\>5
Not applicable, there is no intervention description in this study.
non-CRD
patients whose PSQI score ≦ 5
Not applicable, there is no intervention description in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Not applicable, there is no intervention description in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* elective sublobectomy for primary lung tumor
* ASA grade I-II
* Informed consent of the patient or family
Exclusion Criteria
* Combination of other cancers
* untreated active lung infection
* patients with preoperative neoadjuvant radiotherapy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weifeng Yu
Role: STUDY_DIRECTOR
Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2022-0160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.